Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was originally established in 1999 as a spin-off from Lund University. The business is located in Sweden, where research is conducted in-house but also through international partners. The company is headquartered in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 8,57 | 8,57 | 2024-09-26 |
| Valcuria Holding AB | 3,61 | 3,61 | 2024-09-26 |
| Hans Mandahl | 1,96 | 1,96 | 2024-09-26 |
| Fenja Capital Partners A/S | 1,84 | 1,84 | 2024-09-26 |
| Hartmut Wiese | 1,45 | 1,45 | 2024-09-26 |
| Göran Lennart Rehn | 1,37 | 1,37 | 2024-09-26 |
| Nicholas Peebo | 1,10 | 1,10 | 2024-09-26 |
| Hans Harvig | 0,99 | 0,99 | 2024-09-26 |
| Mattias Nilsson | 0,95 | 0,95 | 2024-09-26 |
| Ulf Stahlin | 0,94 | 0,94 | 2024-09-26 |
2025-02-11 Bokslutskommuniké 2024
